Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents

Cancer Research

Volumn 61, Issue 1, 2001, Pages 228-236

  Candido, Kimberly A ^a,b   Shimizu, Koichi ^b   McLaughlin, Julie C ^b   Kunkel, Robin ^b   Fuller, Jennifer A ^b   Redman, Bruce G ^b   Thomas, Elaine K ^c   Nickoloff, Brian J ^d   Mulé, James J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c AMGEN INC   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR GROWTH;

ANIMALS; ANTIGENS; APOPTOSIS; CELL DIVISION; DENDRITIC CELLS; FEMALE; HEMOCYANIN; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035132829     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. The dendritic cell system and its role in immunogenicity
2. Dendritic cells: Features and functions
3. Induction of antitumor immunity using bone marrow-generated dendritic cells
4. Dendritic cells as adjuvants for immune-mediated resistance to tumors
5. Dendritic cells: A major story unfolds
6. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
7. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
8. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells
9. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
10. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy
11. Getting to the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer
12. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
13. Cross-priming for secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
14. 5and CD36, and cross-present antigens to cytotoxic T lymphocytes
15. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
16. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
17. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells
18. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung
19. Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy
20. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy
21. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V
22. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
23. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
24. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2
25. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic admnidstration of high-dose recombinant interleukin-2
26. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
27. Keyhole limpet hemocyanin (KLH) can enhance the efficacy of tumor lysate-pulsed dendritic cell (DC) immunization in a poorly-immunogenic melanoma model
28. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic ceils induce antitumor immunity
29. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
30. +tumor-infiltrating lymphocytes
31. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response
32. Necrotic cells but not apoptotic ceils induce the maturation of human dendritic cells
33. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
34. +cells
35. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
36. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α
37. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo
38. Identification anti characterization of a new member of the TNF family that induces apoptosis
39. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
40. Tumoricidal activity in tumor necrosis factor-related apoptosis-inducing ligand in vivo
41. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors
42. Preoperative chemotherapy induces apoptosis in early breast cancer
43. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol
44. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin
45. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
46. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
47. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
48. Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells
49. Dendritic cell secretion of IL-15 is induced by recombinant huCD40L and augments the stimulation of antigen-specific cytolytic T cells
50. +T cells
51. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
52. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
53. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
54. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
55. +T cells in vitro
56. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo
57. -subclasses of dendritic cells direct the development of distinct T helper cells in vivo
58. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
59. Therapeutic effects of tumorreactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases